Quantcast

Latest tumour Stories

2014-07-10 12:34:40

Centro Nacional de Investigaciones Oncologicas (CNIO) The pluripotency factor NANOG regulates cell proliferation in epithelia of the skin and oesophagus in adult organisms; blocking the action of the gene diminishes the capacity of tumour cells to divide Scientists from the Spanish National Cancer Research Centre (CNIO) have discovered that NANOG, an essential gene for embryonic stem cells, also regulates cell division in stratified epithelia—those that form part of the epidermis of...

2014-07-07 09:57:58

NUS New study by Cancer Science Institute of Singapore at NUS show that the protein is produced as an immune response and requires the tumour suppressor RUNX3 A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) discovered that a protein named IL23A is part of our stomach’s defense against bacterial infection which leads to gastric cancer. This finding could potentially be used to combat the deadly disease....

2014-07-01 11:38:54

IMIM The identification of new therapeutic targets is urgently needed due to the ineffectiveness of current targets Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer. For the first time they have demonstrated the effects of the inhibition of this protein in mice suffering this type of cancer and the results showed an increase in survival of 20%. The work further suggests...

2014-06-24 14:07:18

Centro Nacional de Investigaciones Oncologicas (CNIO) New mutations in cohesin proteins, which are closely associated with cell division, are very common in various types of cancers such as bladder cancer and melanoma Massive sequencing of cancer genomes brings to light new genes every day that could be involved in the process of tumour formation. A good example of this is cohesin, a ring-shaped protein complex that embraces DNA to control cell division. Just a few months ago, and...

2014-05-27 08:29:47

Fully automated system effectively isolates and retrieves circulating tumour cells for timely, tailored treatment of cancer CHICAGO, May 27, 2014 /PRNewswire/ -- Clearbridge BioMedics will launch its ClearCell(® )FX System at the upcoming American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. This is Clearbridge BioMedics' next-generation device that is able to isolate and capture circulating tumour cells (CTCs)[1] from a blood sample. This is crucial for both research...

2014-04-08 08:31:39

OICR's catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May TORONTO, April 8, 2014 /PRNewswire/ - People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR). The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over...

2014-04-08 08:30:08

CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin,...

2014-01-16 04:20:52

New collaboration aims to push cancer diagnostics to the next level SINGAPORE, Jan. 16, 2014 /PRNewswire/ -- A collaboration between National Cancer Centre Singapore (NCCS) and Clearbridge BioMedics, in partnership with the Pathology Department at Singapore General Hospital (SGH) has resulted in the establishment of the region's first Circulating Tumour Cell Centre of Research Excellence (CTC CoRE). This new Centre facilitates the use of circulating tumour cells (CTCs)[1] in...

2013-09-30 15:52:49

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress (ECC2013). Cediranib, which is taken in pill form, is an inhibitor of a cell signalling process involved in formation of tumour blood vessels, essential for tumour growth, and it is the first oral inhibitor of its kind to show an improvement in the time...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related